These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 32292557)

  • 21. An inhibitor of spleen tyrosine kinase suppresses experimental crescentic glomerulonephritis.
    Han Y; Ma FY; Di Paolo J; Nikolic-Paterson DJ
    Int J Immunopathol Pharmacol; 2018; 32():2058738418783404. PubMed ID: 29923438
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rational design of highly selective spleen tyrosine kinase inhibitors.
    Lucas MC; Goldstein DM; Hermann JC; Kuglstatter A; Liu W; Luk KC; Padilla F; Slade M; Villaseñor AG; Wanner J; Xie W; Zhang X; Liao C
    J Med Chem; 2012 Dec; 55(23):10414-23. PubMed ID: 23151054
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Syk-kinase inhibitor R406 impairs platelet activation and monocyte tissue factor expression triggered by heparin-PF4 complex directed antibodies.
    Lhermusier T; van Rottem J; Garcia C; Xuereb JM; Ragab A; Martin V; Gratacap MP; Sié P; Payrastre B
    J Thromb Haemost; 2011 Oct; 9(10):2067-76. PubMed ID: 21848694
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Crystal structures of spleen tyrosine kinase in complex with novel inhibitors: structural insights for design of anticancer drugs.
    Lee SJ; Choi JS; Han BG; Kim HS; Song HJ; Lee J; Nam S; Goh SH; Kim JH; Koh JS; Lee BI
    FEBS J; 2016 Oct; 283(19):3613-3625. PubMed ID: 27504936
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selective spleen tyrosine kinase inhibition delays autoimmune arthritis in mice.
    Zhang Z; Cao C; Sun S; Xu Q
    Mol Med Rep; 2015 Aug; 12(2):2902-6. PubMed ID: 25955571
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting Syk in Autoimmune Rheumatic Diseases.
    Deng GM; Kyttaris VC; Tsokos GC
    Front Immunol; 2016; 7():78. PubMed ID: 27014261
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The kinase inhibitors R406 and GS-9973 impair T cell functions and macrophage-mediated anti-tumor activity of rituximab in chronic lymphocytic leukemia patients.
    Colado A; Almejún MB; Podaza E; Risnik D; Stanganelli C; Elías EE; Dos Santos P; Slavutsky I; Fernández Grecco H; Cabrejo M; Bezares RF; Giordano M; Gamberale R; Borge M
    Cancer Immunol Immunother; 2017 Apr; 66(4):461-473. PubMed ID: 28011996
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis.
    Coffey G; DeGuzman F; Inagaki M; Pak Y; Delaney SM; Ives D; Betz A; Jia ZJ; Pandey A; Baker D; Hollenbach SJ; Phillips DR; Sinha U
    J Pharmacol Exp Ther; 2012 Feb; 340(2):350-9. PubMed ID: 22040680
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting B-cell receptor signaling kinases in chronic lymphocytic leukemia: the promise of entospletinib.
    Sharman J; Di Paolo J
    Ther Adv Hematol; 2016 Jun; 7(3):157-70. PubMed ID: 27247756
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Novel Triazolopyridine-Based Spleen Tyrosine Kinase Inhibitor That Arrests Joint Inflammation.
    Ferguson GD; Delgado M; Plantevin-Krenitsky V; Jensen-Pergakes K; Bates RJ; Torres S; Celeridad M; Brown H; Burnett K; Nadolny L; Tehrani L; Packard G; Pagarigan B; Haelewyn J; Nguyen T; Xu L; Tang Y; Hickman M; Baculi F; Pierce S; Miyazawa K; Jackson P; Chamberlain P; LeBrun L; Xie W; Bennett B; Blease K
    PLoS One; 2016; 11(1):e0145705. PubMed ID: 26756335
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibitors of switch kinase 'spleen tyrosine kinase' in inflammation and immune-mediated disorders: a review.
    Kaur M; Singh M; Silakari O
    Eur J Med Chem; 2013 Sep; 67():434-46. PubMed ID: 23917087
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Spleen Tyrosine Kinase as a Target Therapy for Pseudomonas aeruginosa Infection.
    Alhazmi A
    J Innate Immun; 2018; 10(4):255-263. PubMed ID: 29925062
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of spleen tyrosine kinase (syk) suppresses renal fibrosis through anti-inflammatory effects and down regulation of the MAPK-p38 pathway.
    Chen KH; Hsu HH; Yang HY; Tian YC; Ko YC; Yang CW; Hung CC
    Int J Biochem Cell Biol; 2016 May; 74():135-44. PubMed ID: 26948651
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study.
    Awan FT; Thirman MJ; Patel-Donnelly D; Assouline S; Rao AV; Ye W; Hill B; Sharman JP
    Leuk Lymphoma; 2019 Aug; 60(8):1972-1977. PubMed ID: 30633573
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of new Syk inhibitors through structure-based virtual screening.
    Huang Y; Zhang Y; Fan K; Dong G; Li B; Zhang W; Li J; Sheng C
    Bioorg Med Chem Lett; 2017 Apr; 27(8):1776-1779. PubMed ID: 28268139
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ligand-based and e-pharmacophore modeling, 3D-QSAR and hierarchical virtual screening to identify dual inhibitors of spleen tyrosine kinase (Syk) and janus kinase 3 (JAK3).
    Kaur M; Silakari O
    J Biomol Struct Dyn; 2017 Nov; 35(14):3043-3060. PubMed ID: 27678281
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer.
    Coffey G; Betz A; DeGuzman F; Pak Y; Inagaki M; Baker DC; Hollenbach SJ; Pandey A; Sinha U
    J Pharmacol Exp Ther; 2014 Dec; 351(3):538-48. PubMed ID: 25253883
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of potent and selective Spleen Tyrosine Kinase inhibitors for the topical treatment of inflammatory skin disease.
    Barker MD; Liddle J; Atkinson FL; Wilson DM; Dickson MC; Ramirez-Molina C; Lewis H; Davis RP; Somers DO; Neu M; Jones E; Watson R
    Bioorg Med Chem Lett; 2018 Nov; 28(21):3458-3462. PubMed ID: 30249354
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-inflammatory actions of Syk inhibitors in macrophages involve non-specific inhibition of toll-like receptors-mediated JNK signaling pathway.
    Lin YC; Huang DY; Chu CL; Lin WW
    Mol Immunol; 2010 Apr; 47(7-8):1569-78. PubMed ID: 20138367
    [TBL] [Abstract][Full Text] [Related]  

  • 40. JTE-852, a novel spleen tyrosine kinase inhibitor, blocks immunoglobulin G-mediated cellular responses and autoimmune reactions in vivo.
    Kato T; Ohta T; Iwasaki H; Kobayashi H; Matsuo A; Hata T; Matsushita M
    Life Sci; 2017 Dec; 191():166-174. PubMed ID: 29056373
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.